Logo

Transgenomic Extends Licensing Agreement with Geron

Sep 25, 2003

NEW YORK, Sept. 25 (GenomeWeb News) - Transgenomic will provide an additional supply of modified nucleic acid building-block compounds to Geron, which will use the technology to synthesize one of its thiophosphoramidate-based telomerase inhibitor cancer drugs.


Transgenomic CEO Collin D'Silva said the extended non-exclusive licensing agreement will enable Transgenomic to manufacture phosphoramidate-based oligonucleotides and the chemical building blocks required for their synthesis "for use in diagnostic and therapeutic applications by other biotechnology, pharmaceutical and diagnostics companies to the mutual benefit of both Transgenomic and Geron."

 

Geron said it will use the technology to help develop its cancer drug GRN163L, formerly known as GRN719.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.